NEW YORK (360Dx) – A team led by researchers at Duke University and the University of California, Los Angeles has developed an inkjet-printed proof-of-concept platform that they said could enable the use of point-of-care tests for the broad range of medical conditions already served by sandwich antibody immunoassays, or ELISAs.
Get the full story with
360Dx Premium
Only $95 for the
first 90 days*
360Dx Premium gives you:
✔ Full site access
✔ Interest-based email alerts
✔ Access to archives
Never miss another important industry story.
You may already have institutional access!
Already a 360Dx or GenomeWeb Premium member?
Login Now.
*Before your trial expires, we’ll put together a custom quote with your long-term premium options.
Not ready for premium?
Register for Free ContentYou can still register for access to our free content.